What is B. Riley's Forecast for CAPR Q2 Earnings?

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Research analysts at B. Riley issued their Q2 2025 EPS estimates for shares of Capricor Therapeutics in a report issued on Wednesday, June 25th. B. Riley analyst M. El-Saadi expects that the biotechnology company will post earnings per share of ($0.48) for the quarter. B. Riley currently has a "Strong-Buy" rating on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. B. Riley also issued estimates for Capricor Therapeutics' Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at $1.37 EPS, FY2027 earnings at ($0.27) EPS, FY2028 earnings at $1.47 EPS and FY2029 earnings at $2.59 EPS.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The firm had revenue of $2.73 million during the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.42%. During the same period last year, the company posted ($0.31) EPS.

Other research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Jones Trading reduced their price objective on Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday, June 25th. HC Wainwright reiterated a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, June 24th. Finally, Roth Capital restated a "buy" rating and issued a $31.00 target price on shares of Capricor Therapeutics in a report on Tuesday, June 17th. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Capricor Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $32.22.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR traded up $0.08 during mid-day trading on Monday, hitting $10.10. 756,387 shares of the company's stock traded hands, compared to its average volume of 1,968,758. Capricor Therapeutics has a 1 year low of $3.52 and a 1 year high of $23.40. The company has a market cap of $461.14 million, a PE ratio of -7.11 and a beta of 0.82. The firm's 50 day simple moving average is $10.70 and its 200 day simple moving average is $12.28.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Summit Investment Advisors Inc. increased its position in shares of Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 1,345 shares in the last quarter. Krilogy Financial LLC boosted its position in Capricor Therapeutics by 9.6% during the 1st quarter. Krilogy Financial LLC now owns 22,800 shares of the biotechnology company's stock worth $216,000 after purchasing an additional 2,000 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Capricor Therapeutics by 2.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company's stock valued at $1,079,000 after purchasing an additional 2,314 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Capricor Therapeutics by 22.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock valued at $178,000 after purchasing an additional 2,361 shares during the period. Finally, Invesco Ltd. lifted its stake in shares of Capricor Therapeutics by 20.5% during the fourth quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company's stock worth $203,000 after purchasing an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.